Given that maladaptive fibrosis is a principal determinant of heart failure following myocardial infarction, targeting the UCK2/UCKL1-TRIM21 regulatory node offers a promising therapeutic strategy to arrest fibrogenesis and improve clinical outcomes in ischemic heart disease. This evidence concerns the gene UCKL1 and heart failure.